Drug Trial Radar · NCT06462586
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Jun 19, 2024
Primary completion
Feb 24, 2026
Study completion Mar 5, 2026
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Conditions
- Bipolar Disorder, Manic
Interventions
LumateperoneDrug
Lumateperone 42 mg capsules administered orally, once daily
PlaceboDrug
Matching capsules administered orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Young Mania Rating Scale (YMRS)Time frame: Week 3
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Site
Rogers, Arkansas
Clinical Site
Bellflower, California
Clinical Site
Culver City, California
Clinical Site
Garden Grove, California
Clinical Site
Lemon Grove, California
Clinical Site
Montclair, California
Clinical Site
Hallandale, Florida
Clinical Site
Hialeah, Florida
Clinical Site
Miami, Florida
Clinical Site
Miami Gardens, Florida
Clinical Site
Miami Lakes, Florida
Clinical Site
Miami Springs, Florida
Clinical Site
Orlando, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Atlanta, Georgia
Clinical Site
Decatur, Georgia
Clinical Site
Savannah, Georgia
Clinical Site
Shreveport, Louisiana
Clinical Site
Marlton, New Jersey
Clinical Site
North Canton, Ohio
Clinical Site
Austin, Texas
Clinical Site
Austin, Texas
Clinical Site
DeSoto, Texas
Clinical Site
Lovech, Bulgaria
Clinical Site
Rousse, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Stara Zagora, Bulgaria
Clinical Site
Veliko Tarnovo, Bulgaria
Clinical Site
Vratsa, Bulgaria
Clinical Site
Split, Croatia
Clinical Site
Zagreb, Croatia
Clinical Site
Zagreb, Croatia
Clinical Site
Guwahati, Assam, India
Clinical Site
Mangalore, Karnataka, India
Clinical Site
Mysore, Karnataka, India
Clinical Site
Nashik, Maharashtra, India
Clinical Site
Ludhiana, Punjab, India
Clinical Site
Belgrade, Serbia
Clinical Site
Kovin, Serbia
Clinical Site
Kragujevac, Serbia
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.